1. Articles in category: Immune Therapy

    1-24 of 332 1 2 3 4 ... 12 13 14 »
    1. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors

      Significant antitumor effects have been observed in a variety of malignancies via blockade of immune checkpoints. Interaction of programmed death 1 (PD-1) with its ligands PD-L1 and PD-L2 suppresses T-cell function and restricts immune-mediated tumor killing. We examined expression of these proteins in children with solid tumors, as expression may serve as biomarkers of response to this class of drugs.

      Read Full Article
      Mentions: PD-1 Biomarkers
    2. Testing a new immunotherapy treatment for neuroblastoma

      Testing a new immunotherapy treatment for neuroblastoma

      Immunotherapies are changing the outlook for many cancer patients.

      Drugs that block cancer cells from deflecting an immune attack are now routinely used to treat advanced skin and kidney cancers, and are showing promise in other types of cancer too.

      But cancers are complex and diverse – what works well against one type of cancer might have little effect against another. The immunotherapies available for some patients aren’t a magic bullet that will work for everyone.

      Read Full Article
    3. Chemoimmunotherapeutic effect of combined treatment with ex vivo generated antigen-presenting immune cells and conventional antitumor agents in a mouse neuroblastoma model.

      Chemoimmunotherapeutic effect of combined treatment with ex vivo generated antigen-presenting immune cells and conventional antitumor agents in a mouse neuroblastoma model.

      J Pediatr Surg. 2017 Apr 21;:

      Authors: Inoue S, Setoyama Y, Odaka A, Kitagawa D, Beck Y

      Read Full Article
      Mentions: Treatment
    4. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      J Control Release. 2017 Apr 12;:

      Authors: Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Mar Ferrandiz M, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NV, Mora J, Sosnik A, Carcaboso AM

      Read Full Article
    5. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

      Chimeric antigen receptor–modified T cells (CAR T cells) produce proinflammatory cytokines that increase expression of T-cell checkpoint signals such as PD-L1, which may inhibit their functionality against solid tumors. In this study, we evaluated in human tumor xenograft models the proinflammatory properties of an oncolytic adenovirus (Onc.Ad) with a helper-dependent Ad (HDAd) that expresses a PD-L1 blocking mini-antibody (mini-body; HDPDL1) as a strategy to enhance CAR T-cell killing.

      Read Full Article
      Mentions: Antibody PD-1
    6. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.

      Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.

      Int J Oncol. 2017 Apr 07;:

      Authors: Horwacik I, Rokita H

      Abstract Children diagnosed with high risk neuroblastoma have poor prognosis which stimulates efforts to broaden therapies of the neoplasm. GD2-ganglioside (GD2) marks neuroblastoma cells and is a target for monoclonal antibodies.

      Read Full Article
      Mentions: Antibody Treatment
    7. Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567

      Authors: McGinty L, Kolesar J

      Abstract PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.

      Read Full Article
      Mentions: Treatment
    8. Orphan designation: Iodine (131I) murine IgG1 monoclonal antibody against CD276, for the: Treatment of neuroblastoma

      Review of designation Orphan designation On 27 February 2017, orphan designation (EU/3/17/1839) was granted by the European Commission to Y-mAbs Therapeutics A/S, Denmark, for iodine ( 131 I) murine IgG1 monoclonal antibody against CD276 (also known as 131 I-mu8H9) for the treatment of neuroblastoma. What is neuroblastoma? Neuroblastoma is a cancer of certain nerve cells which is usually seen as a lump in the abdomen or around the spine.

      Read Full Article
      Mentions: Antibody Treatment
    9. Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy

      Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy

      ​WASHINGTON — Among patients with high-risk neuroblastoma, those who had a certain combination of genotypes gained substantial benefit from adding immunotherapy to isotretinoin treatment, while it is uncertain whether those who lacked the combination gained benefit from immunotherapy, according to results from a randomized phase III clinical trial presented here at the AACR Annual Meeting 2017, April 1-5.

      Read Full Article
    10. Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.

      Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.

      Mol Ther. 2017 Mar 21;:

      Authors: Fisher J, Abramowski P, Wisidagamage Don ND, Flutter B, Capsomidis A, Cheung GW, Gustafsson K, Anderson J

      Abstract Chimeric antigen receptors (CARs) combine T cell activation with antibody-mediated tumor antigen specificity, bypassing the need for T cell receptor (TCR) ligation.

      Read Full Article
      Mentions: Antibody
    11. HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      Am J Cancer Res. 2017;7(2):334-345

      Authors: Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y, He Y

      Read Full Article
    12. Bronchiectasis following treatment for high-risk neuroblastoma: A case series.

      Bronchiectasis following treatment for high-risk neuroblastoma: A case series.

      Pediatr Blood Cancer. 2017 Mar 10;:

      Authors: Adams M, Traunecker H, Doull I, Cox R

      Abstract High-risk (HR) neuroblastoma remains a very challenging disease to treat and long-term cure is only possible with intensive, multimodal treatment including chemotherapy, high-dose therapy, radiotherapy, surgery, and immunotherapy. As a result, treatment-related morbidity and late effects are common in survivors.

      Read Full Article
    13. Bronchiectasis following treatment for high-risk neuroblastoma: A case series

      High-risk (HR) neuroblastoma remains a very challenging disease to treat and long-term cure is only possible with intensive, multimodal treatment including chemotherapy, high-dose therapy, radiotherapy, surgery, and immunotherapy. As a result, treatment-related morbidity and late effects are common in survivors. This report outlines a case series of six patients who developed a chronic productive cough following treatment for HR neuroblastoma.

      Read Full Article
    14. Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy

      Immune checkpoint blockade therapy (ICBT), which blocks negative immune-activating signals and maintains the antitumor response, has elicited a remarkable clinical response in certain cancer patients. However, intrinsic resistance (i.e., insensitivity of the tumors to therapy) remains a daunting challenge. The efficacy of ICBT is tightly modulated by the function of each step in the antitumor immunity cycle. Mechanistically, the number of mutations determines tumor immunogenicity.

      Read Full Article
    15. Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells.

      Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells.

      Clin Cancer Res. 2017 Feb 09;:

      Authors: Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, Rossig C, Rooney CM

      Read Full Article
    16. Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.

      Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.

      Oncotarget. 2017 Jan 28;:

      Authors: Currier MA, Sprague L, Rizvi TA, Nartker B, Chen CY, Wang PY, Hutzen BJ, Franczek MR, Patel AV, Chaney KE, Streby KA, Ecsedy JA, Conner J, Ratner N, Cripe TP

      Read Full Article
    17. GD2-Targeted Immunotherapy and Potential Value of Circulating microRNAs in Neuroblastoma.

      GD2-Targeted Immunotherapy and Potential Value of Circulating microRNAs in Neuroblastoma.

      J Cell Physiol. 2017 Feb 01;:

      Authors: Gholamin S, Miezaei H, Razavi SM, Hassanian SM, Saadatpour L, Masoudifar A, ShahidSales S, Avan A

      Abstract Neuroblastoma (NB) with various clinical presentation is a known childhood malignancy.

      Read Full Article
      Mentions: Immunotherapy
    18. T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNF{alpha} Expression and Empower Adoptive Cell Therapy for Solid Tumors

      Donor-derived allogeneic T cells evoke potent graft versus tumor (GVT) effects likely due to the simultaneous recognition of tumor-specific and host-restricted minor histocompatibility (H) antigens. Here we investigated whether such effects could be reproduced in autologous settings by TCR gene–engineered lymphocytes.

      Read Full Article
    19. Respiratory Difficulties in Children With Underlying Asthma During Immunotherapy for High-risk Neuroblastoma.

      Respiratory Difficulties in Children With Underlying Asthma During Immunotherapy for High-risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Jan 24;:

      Authors: Metrock LK, Qayed M, Simon D, Cash T, O'Connor MG, Johnson S, Esiashvili N, Katzenstein HM

      Abstract Treatment of high-risk neuroblastoma now includes antibody based antitumor immunotherapy as part of standard care.

      Read Full Article
    1-24 of 332 1 2 3 4 ... 12 13 14 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) Immunotherapy
    2. (1 articles) PD-1
    3. (1 articles) Biomarkers
  4. General Informations in the News

    1. (2 articles) Treatment